RecruitingPHASE1, PHASE2NCT06016088
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Respirion Pharmaceuticals Pty Ltd
- Intervention
- RSP-1502(drug)
- Enrollment
- 72 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2024 – 2026
Study locations (22)
- Tucson Cystic Fibrosis Center, Tucson, Arizona, United States
- Center for Cystic Fibrosis at Keck Medical Center of USC, Los Angeles, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- Augusta University, Augusta, Georgia, United States
- The Cystic Fibrosis Institute, Northfield, Illinois, United States
- Tulane University, New Orleans, Louisiana, United States
- The Minnesota Cystic Fibrosis Center, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Columbia University Cystic Fibrosis Program, New York, New York, United States
- Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Dell Children's Medical Center of Central Texas, Austin, Texas, United States
- Royal Prince Albert Hospital, Camperdown, New South Wales, Australia
- Westmead Hospital, Westmead, New South Wales, Australia
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06016088 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS